Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer

Shikha Gaur, Linling Chen, Terence Yen, Yafan Wang, Bingsen Zhou, Mark Davis, Yun Yen

研究成果: 雜誌貢獻文章

37 引文 (Scopus)

摘要

Camptothecin showed remarkable anticancer activity in animal models of cancer but was restricted in clinical use for its adverse toxicity in patients. The preclinical efficacy of CRLX101, a nanoparticle (NP) assembly containing cyclodextrin-based polymer and camptothecin was evaluated by in vitro cytotoxicity in gastric cancer cell lines and in vivo antitumor effects in human gastric cancer cell line BGC823 xenografts. Treated tumor sections were analyzed for presence of NPs and compared with vehicle control tumors for hypoxia and angiogenesis. Gastric cancer cell lines showed high in vitro cytotoxicity for CRLX101 and also showed strong antitumor activity in vivo. Electron micrographs revealed the intracellular presence of NPs in close proximity to vesicles. A significant decrease in expressions of carbonic anhydrase, VEGF, and CD31 proteins in treated tumors indicated an inhibition of hypoxia and angiogenesis. The results provide preclinical data for gastric adenocarcinoma. From the Clinical Editor: This study describes a nanoparticle assembly containing cyclodextrin-based polymer and camptothecin, resulting in increased bioavailability of camptothecin, an effective but toxic anti-cancer agent. The antitumor effects and safety profile were demonstrated in a gastric carcinoma cell line.

原文英語
頁(從 - 到)721-730
頁數10
期刊Nanomedicine: Nanotechnology, Biology, and Medicine
8
發行號5
DOIs
出版狀態已發佈 - 七月 1 2012
對外發佈Yes

指紋

Camptothecin
Cyclodextrins
Stomach Neoplasms
Cells
Tumors
Cell Line
Polymers
Cytotoxicity
Nanoparticles
Neoplasms
Stomach
Carbonic anhydrase
Carbonic Anhydrases
Poisons
Therapeutics
Heterografts
Vascular Endothelial Growth Factor A
Biological Availability
Toxicity
Animals

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Bioengineering
  • Biomedical Engineering
  • Molecular Medicine
  • Materials Science(all)
  • Pharmaceutical Science

引用此文

Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer. / Gaur, Shikha; Chen, Linling; Yen, Terence; Wang, Yafan; Zhou, Bingsen; Davis, Mark; Yen, Yun.

於: Nanomedicine: Nanotechnology, Biology, and Medicine, 卷 8, 編號 5, 01.07.2012, p. 721-730.

研究成果: 雜誌貢獻文章

Gaur, Shikha ; Chen, Linling ; Yen, Terence ; Wang, Yafan ; Zhou, Bingsen ; Davis, Mark ; Yen, Yun. / Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer. 於: Nanomedicine: Nanotechnology, Biology, and Medicine. 2012 ; 卷 8, 編號 5. 頁 721-730.
@article{a066f7fd5f624214a120590972e1610b,
title = "Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer",
abstract = "Camptothecin showed remarkable anticancer activity in animal models of cancer but was restricted in clinical use for its adverse toxicity in patients. The preclinical efficacy of CRLX101, a nanoparticle (NP) assembly containing cyclodextrin-based polymer and camptothecin was evaluated by in vitro cytotoxicity in gastric cancer cell lines and in vivo antitumor effects in human gastric cancer cell line BGC823 xenografts. Treated tumor sections were analyzed for presence of NPs and compared with vehicle control tumors for hypoxia and angiogenesis. Gastric cancer cell lines showed high in vitro cytotoxicity for CRLX101 and also showed strong antitumor activity in vivo. Electron micrographs revealed the intracellular presence of NPs in close proximity to vesicles. A significant decrease in expressions of carbonic anhydrase, VEGF, and CD31 proteins in treated tumors indicated an inhibition of hypoxia and angiogenesis. The results provide preclinical data for gastric adenocarcinoma. From the Clinical Editor: This study describes a nanoparticle assembly containing cyclodextrin-based polymer and camptothecin, resulting in increased bioavailability of camptothecin, an effective but toxic anti-cancer agent. The antitumor effects and safety profile were demonstrated in a gastric carcinoma cell line.",
keywords = "Camptothecin, CPT-11, Gastric cancer, Immunohistochemistry, Nanoparticle, Polymer conjugate",
author = "Shikha Gaur and Linling Chen and Terence Yen and Yafan Wang and Bingsen Zhou and Mark Davis and Yun Yen",
year = "2012",
month = "7",
day = "1",
doi = "10.1016/j.nano.2011.09.007",
language = "English",
volume = "8",
pages = "721--730",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer

AU - Gaur, Shikha

AU - Chen, Linling

AU - Yen, Terence

AU - Wang, Yafan

AU - Zhou, Bingsen

AU - Davis, Mark

AU - Yen, Yun

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Camptothecin showed remarkable anticancer activity in animal models of cancer but was restricted in clinical use for its adverse toxicity in patients. The preclinical efficacy of CRLX101, a nanoparticle (NP) assembly containing cyclodextrin-based polymer and camptothecin was evaluated by in vitro cytotoxicity in gastric cancer cell lines and in vivo antitumor effects in human gastric cancer cell line BGC823 xenografts. Treated tumor sections were analyzed for presence of NPs and compared with vehicle control tumors for hypoxia and angiogenesis. Gastric cancer cell lines showed high in vitro cytotoxicity for CRLX101 and also showed strong antitumor activity in vivo. Electron micrographs revealed the intracellular presence of NPs in close proximity to vesicles. A significant decrease in expressions of carbonic anhydrase, VEGF, and CD31 proteins in treated tumors indicated an inhibition of hypoxia and angiogenesis. The results provide preclinical data for gastric adenocarcinoma. From the Clinical Editor: This study describes a nanoparticle assembly containing cyclodextrin-based polymer and camptothecin, resulting in increased bioavailability of camptothecin, an effective but toxic anti-cancer agent. The antitumor effects and safety profile were demonstrated in a gastric carcinoma cell line.

AB - Camptothecin showed remarkable anticancer activity in animal models of cancer but was restricted in clinical use for its adverse toxicity in patients. The preclinical efficacy of CRLX101, a nanoparticle (NP) assembly containing cyclodextrin-based polymer and camptothecin was evaluated by in vitro cytotoxicity in gastric cancer cell lines and in vivo antitumor effects in human gastric cancer cell line BGC823 xenografts. Treated tumor sections were analyzed for presence of NPs and compared with vehicle control tumors for hypoxia and angiogenesis. Gastric cancer cell lines showed high in vitro cytotoxicity for CRLX101 and also showed strong antitumor activity in vivo. Electron micrographs revealed the intracellular presence of NPs in close proximity to vesicles. A significant decrease in expressions of carbonic anhydrase, VEGF, and CD31 proteins in treated tumors indicated an inhibition of hypoxia and angiogenesis. The results provide preclinical data for gastric adenocarcinoma. From the Clinical Editor: This study describes a nanoparticle assembly containing cyclodextrin-based polymer and camptothecin, resulting in increased bioavailability of camptothecin, an effective but toxic anti-cancer agent. The antitumor effects and safety profile were demonstrated in a gastric carcinoma cell line.

KW - Camptothecin

KW - CPT-11

KW - Gastric cancer

KW - Immunohistochemistry

KW - Nanoparticle

KW - Polymer conjugate

UR - http://www.scopus.com/inward/record.url?scp=84862689147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862689147&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2011.09.007

DO - 10.1016/j.nano.2011.09.007

M3 - Article

C2 - 22033079

AN - SCOPUS:84862689147

VL - 8

SP - 721

EP - 730

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

IS - 5

ER -